Chrysanthemum morifolium Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis.

Abstract

It is well known that the anthracycline anticancer drug doxorubicin (DOX) induces cardiotoxicity. Recently, Chrysanthemum morifolium extract (CME), an extract of the purple chrysanthemum flower, has been reported to possess various physiological activities such as antioxidant and anti-inflammatory effects. However, its effect on DOX-induced cardiotoxicity is still unknown. An 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT)assay revealed that 1 mg/mL of CME reduced DOX-induced cytotoxicity in H9C2 cells but not in MDA-MB-231 cells. A TUNEL assay indicated that CME treatment improved DOX-induced apoptosis in H9C2 cells. Moreover, DOX-induced increases in the expression levels of p53, phosphorylated p53, and cleaved caspase-3,9 were significantly suppressed by CME treatment. Next, we investigated the effect of CME in vivo. The results showed that CME treatment substantially reversed the DOX-induced decrease in survival rate. Echocardiography indicated that CME treatment also reduced DOX-induced left ventricular systolic dysfunction, and a TUNEL assay showed that CME treatment also suppressed apoptosis in the mouse heart. These results reveal that CME treatment ameliorated DOX-induced cardiotoxicity by suppressing apoptosis. Further study is needed to clarify the effect of CME on DOX-induced heart failure in humans.

• Authors: Masaya Ono, Yoichi Sunagawa, Saho Mochizuki, Takahiro Katagiri, Hidemichi Takai, Sonoka Iwashimizu, Kyoko Inai, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Yasufumi Katanasaka, Maki Komiyama, Philip Hawke, Hideo Hara, Yoshiki Arakawa, Kiyoshi Mori, Akira Asai, Koji Hasegawa, Tatsuya Morimoto
• Journal: Cancers (Cancers (Basel)) Vol. 14 Issue 3 (Jan 28 2022) ISSN: 2072-6694 [Print] Switzerland
• PMID: 35158951 (Publication Type: Journal Article)